Etoxi 60/Etoxi 90/Etoxi 120

Symptomatic relief of OA, RA, ankylosing spondylitis; pain & signs of inflammation associated w/ acute gouty arthritis. Short-term treatment of moderate pain associated w/ dental surgery.

OA 30 mg once daily, may be increased to 60 mg once daily. RA, ankylosing spondylitis 90 mg once daily. Acute gouty arthritis 120 mg once daily for 8 days. Postop dental surgery 90 mg once daily. Max: 3 days. Patient w/ mild hepatic dysfunction (Child-Pugh score 5-6) 60 mg once daily, Moderate hepatic dysfunction (Child-Pugh score 7-9) 30 mg once daily.

May be taken with or without food.

Active peptic ulceration or active GI bleeding. Bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or allergic type reactions after taking ASA or NSAIDs (including COX-2 inhibitors). Inflammatory bowel disease. CHF. Patients w/ HTN whose BP is persistently elevated above 140/90 mmHg & has not been adequately controlled. Established ischaemic heart disease, peripheral arterial disease &/or cerebrovascular disease. Severe hepatic dysfunction. Estimated renal CrCl <30 mL/min. Pregnancy & lactation. Childn & adolescents <16 yr.

Serious skin reactions including exfoliative dermatitis, SJS & TEN. Discontinue treatment at the 1st appearance of skin rash, mucosal lesions or sign of hypersensitivity. Upper GI complications, perforations, ulcers or bleedings; MI & stroke; careful considerations in patients w/ HTN, hyperlipidaemia, DM, smoking. Monitor renal function in patients w/ pre-existing renal impairment, uncompensated heart failure or cirrhosis. Fluid retention, oedema. Patients w/ history of cardiac failure, left ventricular dysfunction, or HTN & w/ pre-existing oedema from any other reason. Elevations of ALT/AST or any signs & symptoms suggesting liver dysfunction or in whom an abnormal LFT has occurred. Patients w/ dehydration. May mask fever & other signs of inflammation. Co-administration w/ warfarin or other oral anticoagulants. Not to be given in patients w/ galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Renal, hepatic or cardiac dysfunction. Elderly. Not recommended in women attempting to conceive.

Abdominal pain. Alveolar osteitis; oedema/fluid retention; dizziness, headache; palpitations, arrhythmia; HTN; bronchospasm; constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer; increased ALT/AST; ecchymosis; asthenia/fatigue, flu-like disease.

Increase prothrombin time w/ oral anticoagulants. May reduce the effects of diuretics & other antihypertensive drugs. Increased rate of GI ulceration or other complications w/ ASA. May increase nephrotoxic effect of ciclosporin & tacrolimus. Decrease lithium renal excretion therefore increase in lithium plasma levels. Increase plasma conc & reduce renal clearance of MTX. Increased AUC w/ OCs, HRT, ketoconazole. Monitor digoxin toxicity in high-risk patients. Increased serum conc of ethinyl estradiol. Not recommended in combination w/ rifampicin.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

Rx